Team:Paris Bettencourt/Notebook/Trojan Horse/Friday 28th June

From 2013.igem.org

(Difference between revisions)
(Created page with "<html> <div id"container"> <div id="noteimg"> <a href="https://2013.igem.org/Team:Paris_Bettencourt/Project/Trojan_Horse"> <img src="https://static.igem.org/mediawiki/2013/0/00/PB_Troja...")
Line 1: Line 1:
-
<html>
+
 
<div id"container">
<div id"container">
<div id="noteimg">
<div id="noteimg">
Line 10: Line 10:
<div >
<div >
<div class="FU_note">
<div class="FU_note">
 +
<html>
<p>
<p>
sRNA design<br />
sRNA design<br />
Line 24: Line 25:
We decided that targeting only two different antibiotic resistance will be enough for a proof of concept. We give up AmpR because otherwise they might be experimental issues with AmpR that is also on phagemid litmus28i.  
We decided that targeting only two different antibiotic resistance will be enough for a proof of concept. We give up AmpR because otherwise they might be experimental issues with AmpR that is also on phagemid litmus28i.  
</p>
</p>
-
</div>
 
</html>
</html>
 +
</div>

Revision as of 09:29, 29 July 2013

<a href="https://2013.igem.org/Team:Paris_Bettencourt/Project/Trojan_Horse"> <img src="PB_Trojan_Horse_logo.png" height="30px" width="30px">

</a>

Add here your twit </br>

sRNA design

sRNA Design

Red sequences:

pACYCDuet-1 (CmR) : ATATCCAGTGATTTTTTTCTCCAT
pCOLADuet-1 (KanR) : CGTTTCCCGTTGAATATGGCTCAT

We decided that targeting only two different antibiotic resistance will be enough for a proof of concept. We give up AmpR because otherwise they might be experimental issues with AmpR that is also on phagemid litmus28i.